RxDoctor Payments Data

Melissa Lewis, PA

Medical · Greenville, NCNPI 1912979295

Payments from drug & device makers

$1,404in general payments, 2019–2025

Across 80 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$557
  • Sequel Med Tech, LLC$186
  • Novo Nordisk$98
  • Corcept Therapeutics$72
  • Galderma Laboratories, L.p.$71
  • Lilly USA, LLC$61
  • plus $359 from 13 others

What the payments were for

  • Food & beverage$1,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 70th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$157,983
Medicare patients
261
Services billed
6,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide730$839,327
JardianceEmpagliflozin316$236,509
MounjaroTirzepatide156$188,467
Tresiba Flextouch U-100Insulin Degludec204$144,526
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog201$134,730
TrulicityDulaglutide108$133,534
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/782$85,871
Fiasp FlextouchInsulin Aspart (Niacinamide)60$78,226
Tresiba Flextouch U-200Insulin Degludec44$77,014
Repatha SureclickEvolocumab75$60,494
FarxigaDapagliflozin Propanediol63$53,253
RybelsusSemaglutide53$50,702
Novolog FlexpenInsulin Aspart151$44,524
Humalog Kwikpen U-100Insulin Lispro129$38,579
TymlosAbaloparatide13$33,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$98$890,029783 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$61$338,160356 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$12$255,014348 claims
Radius Health, Inc.Tymlos$28$33,86413 claims
AbbVieSynthroid$26$15,282166 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$2,187240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 medical providers in North Carolina.

Other medical in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →